Relevant bibliographies by topics / Neutropeni

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Neutropeni'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neutropeni.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Neutropeni"

1

Agnes, Marshalla, Pudjo Hagung Widjajanto, and Wahyu Damayanti. "Kejadian Demam Neutropeni pada Leukemia Limfoblastik Akut Anak di RSUP Dr. Sardjito, Yogyakarta." Sari Pediatri 20, no. 6 (May 16, 2019): 360. http://dx.doi.org/10.14238/sp20.6.2019.360-5.

Full text
Abstract:
Latar belakang. Leukemia limfoblastik akut (LLA) merupakan keganasan yang sering ditemukan pada anak dan remaja. Demam neutropeni (DN) merupakan kedaruratan medik pada LLA yang sering menyebabkan kematian.Tujuan. Mengetahui angka kejadian dan kematian DN pada LLA anak selama terapi fase induksi.Metode. Penelitian deskriptif dengan disain potong lintang. Subjek adalah pasien LLA anak pada kurun Januari 2013 hingga Desember 2015, usia 1 bulan hingga 18 tahun dan tengah menjalani terapi fase induksi. Neutropeni ditegakkan dengan jumlah neutrofil absolut <1.500/mmk. Pengambilan sampel dilakukan secara consecutive sampling.Hasil. Terdapat 246 kasus LLA baru pada kurun waktu penelitian, 115 (46,7%) mengalami DN selama fase induksi. Kematian terjadi pada 15/115 (13%) kasus, 9/15 (60%) berhubungan dengan DN (sepsis, syok sepsis), sisanya karena sebab lainnya (sindrom lisis tumor, herniasi dan infiltrasi mening). Analisis pada kasus yang rekam mediknya selama fase induksi lengkap (59/115 atau 51,3%) menunjukkan 50/59 (84%) subjek mengalami satu kali kejadian DN, sisanya 9/59 (16%) mengalaminya 2-3 kali. Median terjadinya DN kali pertama setelah diagnosis adalah 8 hari (0-62 hari). Median durasi DN 7 hari (3-23).Kesimpulan. Kejadian demam neutropeni selama fase induksi masih tinggi dan merupakan penyebab kematian yang paling utama.
APA, Harvard, Vancouver, ISO, and other styles
2

Quirion, Eva. "Filgrastim and Pegfilgrastim Use in Patients With Neutropeni." Clinical Journal of Oncology Nursing 13, no. 3 (June 1, 2009): 324–28. http://dx.doi.org/10.1188/09.cjon.324-328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lahlimi, Fatima Ezzahra, Khawla Khalil, Soumia Lahiaouni, and Illias Tazi. "Neutropenic Enterocolitis Disclosing an Underlying Cyclic Neutropenia." Case Reports in Pediatrics 2020 (December 1, 2020): 1–3. http://dx.doi.org/10.1155/2020/8858764.

Full text
Abstract:
Neutropenic enterocolitis is a syndrome characterized by fever and abdominal pain in a neutropenic patient. It is often reported in children treated for leukemia and rarely reported in patients with other diseases. Herein, we report the case of a 9-year-old patient with a medical history of recurrent fever and mouth ulcers since the age of 4, who presented with neutropenic enterocolitis complicated with intestinal perforation which all leaded to disclose cyclic neutropenia. The patient was successfully treated by aggressive supportive care combined with surgical intervention. Neutropenic enterocolitis with possible complications should be considered and promptly managed in every neutropenic patient and may reveal a rare cause of neutropenia as cyclic neutropenia.
APA, Harvard, Vancouver, ISO, and other styles
4

Pichereau, Solen, Anne Le Louarn, Thierry Lecomte, Hélène Blasco, Chantal Le Guellec, and Hélène Bourgoin. "Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer." Journal of Pharmacy & Pharmaceutical Sciences 13, no. 4 (January 3, 2011): 615. http://dx.doi.org/10.18433/j3wk5s.

Full text
Abstract:
PURPOSE: Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant, are associated with the severity of the bone marrow suppression in patients with metastatic colorectal cancer receiving irinotecan. This study assesses the cost-effectiveness of screening for UGT1A1*28 polymorphism associated with primary prophylactic Granulocytes Colony Stimulating Factor in patients homozygous for the *28 allele. The effectiveness was estimated based on the number of neutropenia avoided. METHODS: We modelled a theoretical population treated with combined 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for metastatic colorectal cancer. A decision tree simulated the health outcomes, measured by the prevalence of neutropenic events for two strategies, with or without UGT1A1 genotype screening. The model incorporated direct hospital costs and was validated with a sensitivity analysis. We calculated the cost-effectiveness ratio: CE=∆C / ∆E = "genotyping" cost – "no genotyping" cost / number of febrile neutropenia avoided. RESULTS: In the "genotyping strategy", the cost to avoid one febrile neutropenia event per 1000 patients treated was € 942.8 to € 1090.1. The sensitivity analysis showed a better CE ratio of € 733.4 to € 726.6 per febrile neutropenic event avoided.CONCLUSIONS: UGT1A1 genotype screening before irinotecan treatment is a cost-efficient strategy for the hospital. Systematic genotyping prior to chemotherapy, and administration of CSF in patients homozygotes for the *28 allele allow to avoid 91 febrile neutropenias at an acceptable cost.
APA, Harvard, Vancouver, ISO, and other styles
5

Sugahara, Hiroyuki, Masao Mizuki, Sayoko Matsumae, Yoshiko Nabetani, Motoko Kikuchi, and Yuzuru Kanakura. "Footwear Exchange Has No Influence on the Incidence of Febrile Neutropenia in Patients Undergoing Chemotherapy for Hematologic Malignancies." Infection Control & Hospital Epidemiology 25, no. 1 (January 2004): 51–54. http://dx.doi.org/10.1086/502292.

Full text
Abstract:
AbstractObjective:To determine whether footwear exchange affects the incidence of febrile neutropenia among patients undergoing chemotherapy for hematologic malignancies.Design:Open trial with historical comparison.Setting:The 12-bed high-efficiency particulate air-fil-tered hematology unit at Osaka University Hospital, Suita, Japan.Patients:Those with hematologic malignancies who underwent chemotherapy from January 1997 through January 2003. Footwear exchange was discontinued in January 2000.Methods:The surveillance system was based on the National Nosocomial Infections Surveillance System of the Centers for Disease Control and Prevention. Rates of febrile neutropenia were calculated for neutropenic patient-days (ie, days with neutropenia < 500/μL).Results:From January 1997 through December 1999 and from February 2000 through January 2003, 58 and 54 patients endured 237 and 184 neutropenic periods following chemotherapy, and their total neutropenic days were 3,123 and 2,503, respectively. They showed episodes of febrile neutropenia 89 and 68 times, respectively. Infection rates were 28.5 and 27.2 per 1,000 neutropenic patient-days (P = .83), respectively.Conclusion:The incidence of febrile neutropenia was not affected by footwear exchange. In hematology units, changing shoes does not appear to affect the rate of infections during neutropenic periods.
APA, Harvard, Vancouver, ISO, and other styles
6

Palmblad, Jan, and Helen A. Papadaki. "Chronic idiopathic neutropenias and severe congenital neutropenia." Current Opinion in Hematology 15, no. 1 (January 2008): 8–14. http://dx.doi.org/10.1097/moh.0b013e3282f172d3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Strojnik, Ksenija, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, and Bostjan Seruga. "Outcome of severe infections in afebrile neutropenic cancer patients." Radiology and Oncology 50, no. 4 (December 1, 2016): 442–48. http://dx.doi.org/10.1515/raon-2016-0011.

Full text
Abstract:
Abstract Background In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. Patients and methods We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011. The outcome of interest was 30-day in-hospital mortality rate. Association between the febrile status and in-hospital mortality rate was evaluated by the Fisher’s exact test. Results We identified 69 episodes of severe neutropenic infections in 65 cancer patients. Among these, 9 (13%) episodes were afebrile. Patients with afebrile neutropenic infection presented with hypotension, severe fatigue with inappetence, shaking chills, altered mental state or cough and all of them eventually deteriorated to severe sepsis or septic shock. Overall 30-day in-hospital mortality rate was 55.1%. Patients with afebrile neutropenic infection had a trend for a higher 30-day in-hospital mortality rate as compared to patients with febrile neutropenic infection (78% vs. 52%, p = 0.17). Conclusions Afebrile cancer patients with chemotherapy-induced neutropenia and severe infections might have worse outcome as compared to cancer patients with febrile neutropenia. Patients should be informed that severe neutropenic infection without fever can occasionally occur during cancer treatment with chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
8

Hapsari, M. M., Helmia Farida, Monique Keuter, P. J,van den Broek, Usman Hadi, Herawati Y, and Anggoro DB Sachro. "Penurunan Penggunaan Antibiotik pada Pasien Anak dengan Demam." Sari Pediatri 8, no. 1 (December 5, 2016): 16. http://dx.doi.org/10.14238/sp8.1.2006.16-24.

Full text
Abstract:
Latar belakang. Resistensi antibiotik saat ini menjadi problem dunia yang mencemaskan.Penggunaan antibotik secara berlebihan dan tidak rasional merupakan kontributor utamaterjadinya resistensi antibiotik. Upaya mengubah pola peresepan antibiotik menjadi lebihrasional merupakan hal yang tidak mudah.Tujuan. Memperbaiki kuantitas dan kualitas penggunaan antibiotik pada pasien yangdirawat dengan demam, serta mengevaluasi dampak terhadap morbiditas dan mortalitas.Metoda. Penelitian prospektif intervensi di bangsal anak RS Dr Kariadi, Juli 2003 -Desember 2004, dibagi menjadi 4 periode yaitu periode awal, penyusunan pedoman,pelatihan, dan umpan balik. Pada periode awal dilakukan pengambilan data dasar. Padaperiode penyusunan pedoman dilakukan konsensus untuk menyusun pedoman penggunaanantibiotik pada anak dengan demam. Periode pelatihan adalah sosialisasi dan pelatihankepada dokter. Pada periode pascapelatihan dilakukan umpan balik terhadap pesertapelatihan. Subyek penelitian adalah semua pasien usia >1 bulan yang dirawat dengandemam> 38ºC (rektal) dalam 24 jam pertama perawatan, kecuali yang diketahui menderitaHIV/AIDS atau neutropeni karena kemoterapi. Data penggunaan antibiotik diambil daricatatan medik, diamati selama 6 hari pertama perawatan. Data morbiditas dan mortalitasdiamati sampai pasien keluar dari rumah sakit. Uji statistik menggunakan X 2 dan Anova.Hasil. Terdapat penurunan kuantitas penggunaan antibiotik dan peningkatan kualitaspenggunaan antibiotik secara bermakna (p=0.000 dan p=0,000). Penurunan kuantitasantibiotiok terutama disebabkan pengurangan penggunaan antibiotik yang tidakdiperlukan. Tidak terdapat perbedaan lama rawat dan lama demam (p=0.96 dan p=0.32)dan tidak terdapat perbedaan kematian selama periode pengamatan.Kesimpulan. Dengan pedoman yang baik, penggunaan jumlah antibiotik dapatditurunkan tanpa meningkatkan risiko morbiditas dan mortalitas.
APA, Harvard, Vancouver, ISO, and other styles
9

Drognitz, Kathrin, Michael Lubbert, Gerald Illerhaus, Frank Gartner, and Hartmut Bertz. "Therapeutic Granulocyte Transfusions in Neutropenic Patients with Invasive Pulmonary Aspergillosis,." Blood 118, no. 21 (November 18, 2011): 3372. http://dx.doi.org/10.1182/blood.v118.21.3372.3372.

Full text
Abstract:
Abstract Abstract 3372 Background: Granulocyte transfusions (GTX) are used as an additional therapeutic option in patients with severe neutropenia following chemotherapy constituting an increased risk for life-threatening bacterial and fungal infections. We hypothesized that interventional GTX would provide a clinical benefit for neutropenic patients with invasive pulmonary aspergillosis (IPA). Methods: We reviewed the clinical outcome of 44 patients with severe neutropenia (46 cases) and underlying hematological malignancies suffering from IPA unresponsive to standard antifungal therapy. They received a total of 181 human recombinant granulocyte colony-stimulating factor (rh G-CSF) stimulated GTX at Freiburg University medical center from 1996 – 2009. Neutropenias were caused by conventional chemotherapy (n=38), conditioning chemotherapy for allogeneic (n=4) and autologous (n=2) hematopoietic cell transplantation (HCT), aplastic anemia (n=1) and by intense immunosuppressive (n=1). Donors were exclusively relatives and acquaintances of the recipients. IPA was diagnosed by clinic, computed tomography (CT) scan, serological or microbiological measures. Response of GTX was evaluated by repeated CT, decreasing C-reactive protein (CRP) levels, hematopoietic regeneration and clearance of serum galactomannan antigen. Results: A median of 3 GTX (range 1–25) containing a median total of 59.4×109 (range 3–170) white blood cells per GTX were administered. All but five (3%) transfusions were well tolerated. Median duration of neutropenia proceeding GTX was 15.5 d (range 4–70). Resolution of infection or clinical improvement was achieved in 29 (63%) patients with IPA and haematopoietic recovery has been assumed within 10 days after the last GTX in 34 patients (74%). Thirty-three (72%) patients were alive one month after the first GTX. Overall, progressive malignant disease was the main cause of death. Patients not responding to GTX died without on septic complications despite appropriate antibacterial and antifungal treatment. Nine out of 26 neutropenic patients receiving GTX after conventional chemotherapy underwent allogeneic HCT later on after control of IPA. Conclusions: Rh G-CSF stimulated GTX are a safe and effective therapeutic tool for patients with hematological malignancies suffering from profound neutropenia and antifungal-therapy resistant IPA. GTX may serve as a bridging therapy in severe neutropenic patients with IPA scheduled for allo-HCT. Disclosures: Bertz: GILEAD: Research Funding; MSD: Membership on an entity's Board of Directors or advisory committees.
APA, Harvard, Vancouver, ISO, and other styles
10

Shahriari, Mahdi, Mohammad Azadbakht, Maryam Roohparvar, Babak Daneshfard, and Majid Nimrouzi. "Effect of chamomile on chemotherapy-induced neutropenia: a pilot open-label controlled trial." Pakistan Journal of Medical and Health Sciences 15, no. 7 (July 30, 2021): 1966–68. http://dx.doi.org/10.53350/pjmhs211571966.

Full text
Abstract:
Neutropenia is a common complication of chemotherapy in leukemic patients. An herbal formulation of chamomile was hypothesized to be effective on neutropenia. A group of healthy volunteers and two groups of patients received chamomile oral drop to be compared with a control group of neutropenic patients. Results showed an increase of white blood cells and resolution of neutropenia in all groups except for the control group. In conclusion, chamomile could be used as an effective complementary medicine for increasing the immunity of neutropenic patients (in addition to healthy individuals). Keywords: Chamomile; Leukemia; Chemotherapy; Neutropenia; Integrative Medicine; Persian Medicine
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Neutropeni"

1

Lilja, Carina, and Karin Svensson. "Omvårdnadsåtgärder vid neutropeni orsakat av cytostatika." Thesis, Malmö högskola, Fakulteten för hälsa och samhälle (HS), 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-24253.

Full text
Abstract:
Lilja, C & Svensson, K. Omvårdnad vid neutropeni orsakat av cytostatika. En litteraturstudie. Examensarbete i omvårdnad 15 högskolepoäng. Malmö Högskola: Hälsa och samhälle, Utbildningsområde omvårdnad, 2008.Neutropeni är en allvarlig komplikation hos patienter som behandlas med cytostatika och är förenat med risk för vårdrelaterade infektioner och sepsis som kan vara livshotande. Ibland behövs skyddsisolering på sjukhus med risk för vårdrelaterade infektioner. Syftet var att ur ett sjuksköterskeperspektiv belysa omvårdnaden under skyddsisoleringen samt vilka infektionsförebyggande åtgärder som är av betydelse. Metoden var en litteraturstudie som bygger på 17 vetenskapliga artiklar. Resultatet visar olika omvårdnadsaspekter som är betydelsefulla vid neutropeni. Olika infektionsförebyggande åtgärder för att hindra endogen och exogen smitta belystes. Smittspridningen förhindras genom användning av basala hygienrutiner och handdesinfektion. Patienter med neutropeni som skyddsisoleras på sjukhus är en utsatt och svårt sjuk patientgrupp vilket gör det svårt att randomisera tillräckligt stora, väldesignade och jämförbara studier. Det saknas forskning inom omvårdnaden. Säkra rekommendationer med hög trovärdighet kan inte ges med denna bakgrund. Behov finns att kritiskt utvärdera de insatser som görs idag och att utveckla forskningen av omvårdnaden av patienter med cytostatikaorsakad neutropeni.
Lilja, C & Svensson, K. Chemically induced neutropenia: The need of nursing care. A literature review. Degree Project, 15 Credit Points. Malmö University: Health and Society, Department of Nursing, 2008.Neutropenia is a serious complication among cancer patients who receive chemotherapy and can cause life threatening cross infections and sepsis. Protective care at hospital is sometimes needed with risk for cross infections. The purpose of this review was to highlight the nursing care of patients in protective care and to indicate the most important actions to prevent cross infections. A literature review was used as method based on seventeen scientific articles. The result showed actions of nursing care that are important during protective care at hospitals. The result also showed interventions to prevent cross infections caused of endogenous and exogenous source. There are few well designed studies and there is a lack of comparable empirical evidence. These patients are very ill and vulnerable and it is difficult to perform randomized studies with enough sample size to get well designed and comparable studies. Therefore recommendations can not be given that are based on high level of evidence. There is a need to develop evidence based nursing methods and to identify and evaluate nursing interventions so that the best possible care of patients with chemically induced neutropenia in protective care is given.
APA, Harvard, Vancouver, ISO, and other styles
2

Sjögren, Erik, and Nellie Haraldsson. "Isoleringsrutiner gällande livsmedelsbegränsningar för patienter på sjukhus där allogena stamcellstransplantationer genomförs." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-314355.

Full text
Abstract:
Bakgrund: Stamcellstransplantation är en behandlingsmetod mot flera olika typer av leukemi. Efter transplantationen blir patienten infektionskänslig. Vid detta tillstånd skyddsisoleras patienten och får en livsmedelsbegränsad kost.Syfte: Sammanställa och jämföra isoleringsrutiner gällande livsmedelsbegränsningar för patienter vid Sveriges hematoloigavdelningar där allogen transplantation sker och jämföra med aktuell forskning bakom livsmedelsbegränsningar.Metod: Tvärsnittsstudie vid jämförelsen av livsmedelsbegränsningarna vid Sveriges hematologiavdelningar samt en litteraturstudie vid undersökningen av aktuell forskning i databaserna Pubmed och Cinahl.Resultat: I tvärsnittsstudien använde alla sjukhusen olika rutiner. Ingen signifikant skillnad gällande infektionsincidensen mellan patienter som hade livsmedelsbegränsningar jämfört med de som inte hade det fanns i litteratursökningen.Slutsats: Livsmedelsbegränsningar minskar troligtvis inte infektionsrisken för infektionskänsliga patienter. Det behövs högkvalitativ forskning för att utforma tydliga riktlinjer kring vilka livsmedelsbegränsningar som bör användas.
Background: Stem cell transplantation is a treatment for patients with leukemia. After the transplantation, the patients are at a higher risk of getting an infection and are therefore kept in protective isolation and get a food restricted diet.Purpose: To compile and compare the differences in food restricted diet for neutropenic patients at the hematology departments in Sweden where stem cell transplantation is performed and compare food restricted diet to current research.Method: A cross-sectional study to compare the food restrictions and a literature study to find out what the current research says using Pubmed and Cinahl.Result: The cross-sectional study showed that all the hospitals used different diets. In the literature review, no significant difference regarding infections rates when comparing patients who ate a food restricted diet with those who did not.Conclusion: Food restrictions are unlikely to reduce the infection rate of neutropenic patients. More high quality research is needed to formulate clear guidelines about what food restricted diet should be used.
APA, Harvard, Vancouver, ISO, and other styles
3

Dufoir, Thierry. "Etude comparative de différentes modalités d'administration de la Vancomycine chez le patient neutropénique." Bordeaux 2, 1993. http://www.theses.fr/1993BOR2P042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Urbonas, Vincas. "Biomarkers of bacteremia and sepsis in pediatric oncology patients with febrile neutropenia." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2013. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2013~D_20131115_080913-61678.

Full text
Abstract:
This study was designed to evaluate the response of innate immunity to acute bacterial inflammation in terms of cytokines and other biomolecules concentration changes in the blood of investigated childhood oncology patients during the beginning of febrile neutropenia (FN) episode and to assess the relevance of these biomarkers for sepsis/bacteremia evaluation. This study was performed at Vilnius University Children Hospital and State Research Institute Centre for Innovative Medicine from 2009 to 2011. Serum samples were collected during 82 fever episodes in a total of 53 oncology patients. The study population consisted of pediatric oncology patients admitted to the hospital with the diagnosis of neutropenia and fever. According to microbiological and clinical findings, patients with episodes of FN were classified into 2 groups: 1) fever of unknown origin (FUO) group – patients with negative blood culture, absence of clinical signs of sepsis and clinically or microbiologically documented local infection, 2) septic/bacteremia (SB) group – patients with positive blood culture (documented Gram-positive or Gram-negative bacteremia) and/or clinically documented sepsis. We measured the levels of cytokines (IL-6, IL-8, IL-10), their receptors (sIL-2R) and other biomarkers (PCT, CRP, sHLA-G) for three consecutive days. We showed that on day 1 the most accurate biomarkers for bacteremia/sepsis discrimination were cytokines (IL-6, IL-10, IL-8), on day 2 – IL-8 and PCT. On day 1 the... [to full text]
Viena iš pagrindinių taikomos šiuolaikinės intensyvios chemoterapijos komplikacijų yra organizmo imuninės sistemos slopinimas ir su tuo susijusi neutropenija, kuri savo ruožtu sąlygoja padidėjusią riziką susirgti bakterinės kilmės infekcinėmis ligomis. Šio darbo tikslas buvo įvertinti ūmaus bakterinio uždegimo bei sepsio patogenezėje dalyvaujančių citokinų (IL-6, IL-8, IL-10), citokinų receptorių (sIL-2R), ūmios fazės baltymų bei kitų imuninio atsako komponentų (CRB, PCT, sHLA-G) tinkamumą bakterinio proceso ankstyvai diagnostikai tarp pacientų su febrline neutropenija (FN), šių biožymenų tinkamumą ir pritaikomumą kasdienėje klinikinėje praktikoje. Tiriamoji medžiaga surinkta 2009–2011 m. Vilniaus universiteto Vaikų ligoninės Onkohematologijos skyriuje. Į tyrimą buvo įtraukta 53 onkohematologinėmis ligomis sergantys vaikai su FN, kurie gydymo eigoje turėjo 82 karščiavimo epizodus. Nuo pirmos karščiavimo dienos tris dienas iš eilės buvo imami kraujo mėginiai bei nustatomos citokinų (IL-6, IL-8, IL-10), CRB, PCT, sHLA-G ir sIL-2R koncentracijos. Remiantis klinikinių bei mikrobiologinių tyrimų duomenimis, FN epizodai buvo suskirstyti į dvi grupes – neaiškios kilmės karščiavimo (NKK), į kurią buvo įtraukti pacientai be sepsio požymių bei su neigiamais mikrobiologiniais pasėliais ir bakteriemijos/sepsio (BS). BS grupę sudarė pacientai su teigiamais mikrobiologiniais pasėliais ir(ar) kliniškai diagnozuotu sepsiu. Mūsų atlikto tyrimo rezultatais bakteriemijos/sepsio vertinimui FN... [toliau žr. visą tekstą]
APA, Harvard, Vancouver, ISO, and other styles
5

Urbonas, Vincas. "Vaikų, sergančių navikinėmis ligomis, bakteriemijos bei sepsio biožymenys febrilinės neutropenijos epizodo metu." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2013. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2013~D_20131115_080926-38717.

Full text
Abstract:
Viena iš pagrindinių taikomos šiuolaikinės intensyvios chemoterapijos komplikacijų yra organizmo imuninės sistemos slopinimas ir su tuo susijusi neutropenija, kuri savo ruožtu sąlygoja padidėjusią riziką susirgti bakterinės kilmės infekcinėmis ligomis. Šio darbo tikslas buvo įvertinti ūmaus bakterinio uždegimo bei sepsio patogenezėje dalyvaujančių citokinų (IL-6, IL-8, IL-10), citokinų receptorių (sIL-2R), ūmios fazės baltymų bei kitų imuninio atsako komponentų (CRB, PCT, sHLA-G) tinkamumą bakterinio proceso ankstyvai diagnostikai tarp pacientų su febrline neutropenija (FN), šių biožymenų tinkamumą ir pritaikomumą kasdienėje klinikinėje praktikoje. Tiriamoji medžiaga surinkta 2009–2011 m. Vilniaus universiteto Vaikų ligoninės Onkohematologijos skyriuje. Į tyrimą buvo įtraukta 53 onkohematologinėmis ligomis sergantys vaikai su FN, kurie gydymo eigoje turėjo 82 karščiavimo epizodus. Nuo pirmos karščiavimo dienos tris dienas iš eilės buvo imami kraujo mėginiai bei nustatomos citokinų (IL-6, IL-8, IL-10), CRB, PCT, sHLA-G ir sIL-2R koncentracijos. Remiantis klinikinių bei mikrobiologinių tyrimų duomenimis, FN epizodai buvo suskirstyti į dvi grupes – neaiškios kilmės karščiavimo (NKK), į kurią buvo įtraukti pacientai be sepsio požymių bei su neigiamais mikrobiologiniais pasėliais ir bakteriemijos/sepsio (BS). BS grupę sudarė pacientai su teigiamais mikrobiologiniais pasėliais ir(ar) kliniškai diagnozuotu sepsiu. Mūsų atlikto tyrimo rezultatais bakteriemijos/sepsio vertinimui FN... [toliau žr. visą tekstą]
This study was designed to evaluate the response of innate immunity to acute bacterial inflammation in terms of cytokines and other biomolecules concentration changes in the blood of investigated childhood oncology patients during the beginning of febrile neutropenia (FN) episode and to assess the relevance of these biomarkers for sepsis/bacteremia evaluation. This study was performed at Vilnius University Children Hospital and State Research Institute Centre for Innovative Medicine from 2009 to 2011. Serum samples were collected during 82 fever episodes in a total of 53 oncology patients. The study population consisted of pediatric oncology patients admitted to the hospital with the diagnosis of neutropenia and fever. According to microbiological and clinical findings, patients with episodes of FN were classified into 2 groups: 1) fever of unknown origin (FUO) group – patients with negative blood culture, absence of clinical signs of sepsis and clinically or microbiologically documented local infection, 2) septic/bacteremia (SB) group – patients with positive blood culture (documented Gram-positive or Gram-negative bacteremia) and/or clinically documented sepsis. We measured the levels of cytokines (IL-6, IL-8, IL-10), their receptors (sIL-2R) and other biomarkers (PCT, CRP, sHLA-G) for three consecutive days. We showed that on day 1 the most accurate biomarkers for bacteremia/sepsis discrimination were cytokines (IL-6, IL-10, IL-8), on day 2 – IL-8 and PCT. On day 1 the... [to full text]
APA, Harvard, Vancouver, ISO, and other styles
6

Rizzo-Padoin, Nathalie. "Modifications pharmacocinétiques des antibiotiques chez le patient neutropénique : application à la téicoplanine." Paris 5, 1995. http://www.theses.fr/1995PA05P175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lafferrerie, Chris. "Evaluation de la tazocilline en monothérapie comme antibiothérapie empirique de première ligne au cours des neutropénies fébriles chez l'adulte suivi pour hémopathie maligne." Bordeaux 2, 1999. http://www.theses.fr/1999BOR2M045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Delebarre, Mathilde. "Prédire l’infection sévère lors des épisodes de neutropénie fébrile post-chimiothérapie de l’enfant : développement d’une règle de décision clinique." Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S018/document.

Full text
Abstract:
Contexte: Le pronostic des neutropénie fébrile (NF) post-chimiothérapie de l’enfant a été amélioré par une antibiothérapie à large spectre systématique. Cependant des infections sévères ne surviennent que dans 15-25% des cas. Il a été recommandé en 2012 de faire évoluer la prise en charge en tenant compte du risque infectieux en utilisant des règles de décision clinique (RDC). Nous avions montré que les outils publiés pour distinguer ce risque étaient peu performants, non validés ou non applicables sur notre population. Une nouvelle RDC (score) permettant de distinguer les épisodes de NF à bas risque d’infection sévère a été construite. Cette RDC a été validée en interne. Compte tenu des différences mises en évidence dans les populations de tumeurs solides et d’hémopathies, il pourrait être pertinent d’utiliser un arbre de décision clinique pour classer le risque infectieux dont la première division serait le type de cancer et de valider cette nouvelle RDC.L’objectif de ce travail était de calibrer cette RDC sous forme d’arbre et de la valider sur un échantillon multicentrique pour distinguer les enfants avec NF à bas risque d’infection sévère. Méthodes: La première étape a été d’évaluer la méthodologie de développement des RDC déjà publiées pour identifier d’éventuelles limites méthodologiques. Ensuite, nous avons décrit les différences entre les hémopathies ou avec les tumeurs solides. Puis, la nouvelle RDC a été calibrée sous forme d’un arbre de décision à l’aide du logiciel Sipina. Sa performance a été évaluée en termes de sensibilité (Se), spécificité (Sp), et rapport de vraisemblance négatif (RVN).En parallèle, un protocole de validation multicentrique prospectif a été monté, avec pour objectif une Se proche de 100% et un RVN inférieur à 0,1. Il a été validé par le CCTIRS et par la CNIL. Il a été financé par la Ligue Contre le Cancer (72 000 euros). Trente et un centres ont été recrutés. La RDC n’a été appliquée qu’a posteriori ; la prise en charge de cette population n’a donc pas été modifiée. La performance de la RDC entre la population de validation et construction a été analysée en termes de Se, Sp, RVN. L’évaluation des pratiques de prise en charge des NF post-chimiothérapie de l’enfant a été faite en parallèle sous la forme d’une enquête nationale, dans la perspective d’une étude d’impact ultérieure.Résultats: L’étude de la méthodologie des RDC déjà publiées a montré que les critères de développement d’une RDC étaient respectés dans 71% des cas (médiane). Une RDC avait atteint le plus haut niveau d’évidence, mais sa population de construction était différente de la nôtre et cette RDC n’était pas reproductible sur notre population. Il existait 2 à 3 fois plus d’infection sévère chez les patients atteints d’une hémopathie maligne. Deux arbres de décision ont donc été construits pour différencier le risque d’infection sévère. Pour les patients avec une tumeur solide il avait des Se de 96%, Sp de 59% et RVN à 0,07, pour ceux avec une hémopathie maligne, il avait des Se de 99%, Sp de 52% et RVN à 0,03. Les inclusions de la validation multicentrique se sont déroulées de janvier 2012 à mai 2016. 1806 épisodes ont été inclus (333 infections sévères, 18,4%). L’application de la RDC a été faite a posteriori(en cours). L’enquête nationale menée en parallèle sur la prise en charge faite en pratique dans les centres français a montré une grande variabilité de prise en charge notamment dans les définitions de la neutropénie et de la fièvre. Un travail doit être initié avec la Société Française des Cancers de l’Enfant pour uniformiser la prise en charge des NF et déterminer le type d’allègement thérapeutique à proposer en vue de l’étude d’impact, en utilisant cette RDC. Conclusion: Les étapes de construction et de validation de cette nouvelle RDC ont été réalisées en respectant les standards méthodologiques. Une étude d’évaluation de l’impact de la RDC devra être mise en place pour atteindre le plus haut niveau d’évidence
Purpose: Chemotherapy-induced febrile neutropenia (FN) is known to be a risk for severe infection and death in the absence of prompt and appropriate antibiotic therapy. Immediate hospitalization for rapid institution of empirical broad-spectrum intravenous antibiotic therapy has led to reduce the mortality. However, documented or severe infections occur in only 15-25% of cases. In 2012 paediatric guidelines suggested to adapt the management of FN episodes to the infectious risk. In a previous work, none of the published clinical decision rules (CDRs) to rule out severe infections have been validated and have only rarely been tested in an external set of children. The methodological standards used to derive and validate these CDRs were a real concern. A new CDR was previously derived as a scoring system in Lille to classify the patients at high or low risk of severe infection, with a dataset collected in 2 centers in Lille, in following methodological standards. Differences between solid tumours and blood cancers were observed in children with FN for numbers and types of infections. As a result, we considered relevant to build a decision tree model to predict the low risk for severe infection with a first division that could be the type of cancer. This new decision rule was already validated in an internal set of data, but required an external validation.The aim of this project was to calibrate the CDR as a decision tree and validate its performance a posteriori in an external set of patients, using prospectively collected data from multiple centers.Methods: the methodological standards of available CDRs were first analysed. The new CDR derived on a bicentric dataset was reused to calibrate the CDR as a decision tree, using Sipina software. A prospective multicentric observational protocol funded by 72000€ provided by “la Ligue Contre le Cancer” was developed for an external validation of the CDR to expect near 100% sensitivity (Se) and a negative likelihood ratio (LR) below 0.1. The ethical regulation was followed. Thirty-one centers were recruited in France (27/30 referent centers for management of children with cancer, and 4 proximity centers fit to manage children with FN). The CDR was not applied to the included patients, and remained confidential. The data were collected on an e-CRF “capture system”. The data were captured by an assistant of clinical research and controlled by a physician researcher after the monitoring of the data in all centers. The CDR was a posteriori applied on the dataset. The performance of the CDR between validation and derivation sets of patients was analysed in terms of Se, specificity (Sp) and negative LR.Results: the methodological standards of development of a CDR were not always followed for the development of the published CDR predicting infection for FN in children. Only one CDR followed all criteria and reached the highest level of evidence, but this CDR was built in a very different population from our and was not reproducible. A decision tree model of the CDR was built to distinguish children with FN at low risk of severe infection. For children with solid tumours, the CDR had 96% Se, 59% Sp, and a negative LR at 0.07. For children with blood cancers, the CDR had 99% Se, 52% Sp, and a negative LR at 0.03.For external validation, inclusions started in 2012 until May 2016. Of the 31 centers, 23 included 1806 cases (333 severe infections [18.4%]). The retrospective application of the CDR on all included case in ongoing. A national survey was also conducted as the same time to analyse the real management of children with FN in France in order to determine the type of management that could be proposed for low risk patients when the CDR will be tested in an impact study.Conclusion: the different steps for the construction and validation of the new CDR were conducted following standards. This CDR is in progress to reach the highest level of evidence
APA, Harvard, Vancouver, ISO, and other styles
9

Girod, Caroline. "Le Neupogen* : utilisation et étude à l'hopital Saint-André de Bordeaux." Bordeaux 2, 1994. http://www.theses.fr/1994BOR2P034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bellesso, Marcelo. "Tratamento ambulatorial da neutropenia febril." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-02062009-093637/.

Full text
Abstract:
INTRODUÇÃO: A neutropenia febril (NF) é uma complicação freqüente e potencialmente fatal no manejo do paciente onco-hematológico. Estudos recentes demonstram que a NF consiste em um grupo heterogêneo de pacientes com riscos variados. Nosso objetivo foi avaliar a taxa de falência ao tratamento de primeira linha, taxa de internação e óbito. Além disso, estudamos as variáveis clínico-laboratoriais em relação aos desfechos, a validação do índice Multinational Association for Supportive Care of Cancer (MASCC) modificado e a taxa de positividade de hemocultura e urocultura, como também o perfil de sensibilidade ao cefepima. CASUÍSTICA E METODOLOGIA: Estudo retrospectivo unicêntrico. Os dados foram obtidos através dos prontuários do Hospital-Dia no período de Julho de 2001 a Junho de 2006. Foram avaliados eventos com NF tratados com cefepima 2g (2x/dia), associado ou não, a teicoplamina 400mg/dia. RESULTADOS: Em 128 pacientes, estudamos 178 eventos de NF. A taxa de falência ao tratamento de primeira linha foi de 36,5%, taxa de internação 20,7% e óbito em 6,2% entre os eventos de NF. Na análise multivariada do estudo das categorias clínico-laboratoriais e dos desfechos encontramos como dados significantes em relação ao risco da falência ao tratamento de primeira linha: Idade < 60 anos (OR: 2,11 IC95%: 1,71-2,51, p = 0,004) e creatinina sérica > 1,2mg/dL (OR: 7,19, IC95%: 1,81 30,71 p= 0,005). Os dados significantes para o risco de internação foram: Ausência do diagnóstico de Linfoma não - Hodgkin (OR: 2,42 IC95%: 2,04 2,8, p= 0,011) Tabagismo (OR: 3,14, IC95% 1,14 8,66, p=0,027) e creatinina sérica > 1,2mg/dL (OR: 7,97, IC95% 21,19 - 28,95, p=0,002). Em relação ao óbito, o único dado de risco significante foi a saturação de oxigênio < 95% (OR: 5,8, IC95% 1,50 - 22,56, p = 0,011). Em relação ao índice MASCC modificado e seu impacto sobre os desfechos obtivemos os seguintes resultados: Falência do tratamento de primeira linha e (baixo risco versus alto risco): 35,2% x 53,8%, p=0,232; Internação (baixo risco versus alto risco): 18,2% x 53,8%, p = 0,006; óbito (baixo risco versus alto risco): 4,3% x 30,8%, p=0,004. As taxas de hemocultura e urocultura positivas foram respectivamente: 13% e 8%. O agente isolado mais freqüente nos dois exames foi Eschericia coli. Em relação ao perfil de sensibilidade dos agentes isolados e testados, 100% foram sensíveis ao cefepima. CONCLUSÕES: Os eventos de NF em tratamento ambulatorial apresentaram taxas satisfatórias em relação aos desfechos. Os dados sugerem que os riscos como: Ausência de Linfoma não - Hodgkin, tabagismo, creatinina sérica > 1,2mg/dL e oximetria de pulso < 95% merecem ser considerados como fatores de riscos para desfechos indesejáveis. O índice MASCC modificado mostrou-se eficaz para classificar os eventos classificados como alto risco na nossa população. Em relação aos agentes isolados e testados, 100% são sensíveis ao antibiótico de primeira linha cefepima.
BACKGROUND AND OBJECTIVES: Febrile Neutropenia (FN) is a frequent adverse event and potentially lethal in patients with haematologic malignancies. Nowadays, FN represents a heterogeneous group with different risk for serious complications and death. We studied the first line antibiotic failure, hospitalization rate and death. In addition, it was compared clinical and laboratory data with outcomes, validation of the usefulness of Modified Multinational Association for Supportive Care of Cancer (MASCC) and blood culture and urine culture rate identification. DESIGN AND METHODS: We elaborated a retrospective study. It was evaluated patients with haematologic malignancies who were treated with Cefepime 2g intravenous (IV) twice a day, with or without Teicoplanin 400mg (IV) once a day. RESULTS: Of the 178 FN events, it was observed: first line antibiotic failure 36,5%, hospitalization rate 20,7% and deaths 6,2%. In multivariate analyses, it was evidenced with risk to first line antibiotic failure: Age < 60 years (OR: 2,11, CI95%: 1,71-2,51, p =0,004), serum creatinine > 1,2mg/mL (OR: 7,19, CI95%: 1,81 30,71 p= 0,005). In hospitalization the risks were: Without diagnosis of Non- Hodgkin Lymphoma (OR: 2,42, CI95%: 2,04 2,8, p= 0,011), smoking (OR: 3,14, CI95% 1,14 8,66, p=0,027), serum creatinine > 1,2mg/dL (OR: 7,97, CI95%21,19- 28,95, p=0,002). Relating to death, the risk was transcutaneous oximetry < 95% (OR: 5.8, CI95%: 1.50 22.56, p = 0.011). Analyzing MASCC index, 165 events were classified as low-risk and 13 as high-risk. Outpatient treatment failures were reported in connection with 7 (53.8%) high-risk episodes and 30 (18.2%) low-risk, p=0.006. In addition, death in 7 (4.2%) low-risk and 4 (30.8%) high-risk events, p=0.004. Microbiological infection documented was identified in 13% and 8% in blood cultures and urine cultures, respectively. The most common agent isolated was E. coli and 100% were sensitive to cefepime. INTERPRETATIONS AND CONCLUSIONS: The outpatient treatment with intravenous antibiotic was satisfactory. The risks: Haematologic malignancies other than Non-Hodgkin Lymphoma, smoking, serum creatinine elevated and oximetry < 95% should be considered in FN evaluation. It was validated MASCC index in the Brazilian population. Relating to microbiological agents studied 100% were not resistant for cefepime.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Neutropeni"

1

Klastersky, J. Febrile neutropenia. London: Springer Healthcare, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klastersky, Jean A., ed. Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klastersky, Jean A. Febrile Neutropenia. Tarporley: Springer Healthcare Ltd., 2014. http://dx.doi.org/10.1007/978-1-907673-70-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Velez, Ana Paula, Jorge Lamarche, and John N. Greene, eds. Infections in Neutropenic Cancer Patients. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21859-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lo, Eileen. Neutropenia in children and adolescents: Literature review and case reports. [Toronto: University of Toronto, Faculty of Dentistry], 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Champigneulle, Benoit, and Frédéric Pène. Pathophysiology and management of neutropenia in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0274.

Full text
Abstract:
Neutropenia is defined by an absolute neutrophil count <500 per mm3. Chemotherapy-induced myelosuppression represents the main mechanism accounting for neutropenia, although various bone marrow disorders might also result in impaired granulopoiesis. Neutropenia, especially when profound and prolonged, is a major risk factor for severe bacterial and fungal infections. Early initiation of empirical broad-spectrum antibiotic therapy represents the cornerstone of the treatment of febrile neutropenia. A number of infected neutropenic patients may exhibit organ failures, such as acute respiratory failures and/or severe sepsis requiring intensive care unit (ICU) admission. This chapter discusses the particularities in the management of neutropenic patients in the ICU, including outcome and criteria for ICU admission, management of antimicrobials with respect to the current epidemiological trends, and other measures specific to this subgroup of patients.
APA, Harvard, Vancouver, ISO, and other styles
7

Febrile Neutropenia. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

J, Klastersky, ed. Febrile neutropenia. Berlin: Springer, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kenneth V I Rolston (Editor) and Edward B. Rubenstein (Editor), eds. Textbook of Febrile Neutropenia. Informa Healthcare, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

I, Rolston Kenneth V., and Rubenstein Edward B, eds. Textbook of febrile neutropenia. London: Martin Dunitz, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Neutropeni"

1

Lyman, Gary H. "Neutropenia." In Encyclopedia of Cancer, 2506–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Froehlich, Stephan J., Carlo A. Lackerbauer, Guenter Rudolph, Jan Rémi, Soheyl Noachtar, Werner J. Heppt, Annette Cryer, et al. "Neutropenia." In Encyclopedia of Molecular Mechanisms of Disease, 1469. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_6282.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Boxer, L. A. "Neutropenia." In Practical Algorithms in Pediatric Hematology and Oncology, 42–43. Basel: KARGER, 2003. http://dx.doi.org/10.1159/000069595.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gidvani-Diaz, Vinod K. "Neutropenia." In Benign Hematologic Disorders in Children, 191–203. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49980-8_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brundige, Karyn. "Neutropenia." In Pediatric Oncology, 173–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-87984-8_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Crawford, Jeffrey. "Neutropenia." In Supportive Care in Cancer Therapy, 165–77. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-291-5_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Troicki, Filip T., Filip T. Troicki, Filip T. Troicki, Carlos A. Perez, Wade L. Thorstad, Brandon J. Fisher, Larry C. Daugherty, et al. "Neutropenia." In Encyclopedia of Radiation Oncology, 550. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lyman, Gary H. "Neutropenia." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_4052-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lyman, Gary H. "Neutropenia." In Encyclopedia of Cancer, 3085–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_4052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tattersall, M. H. N. "High-Dose Chemotherapy: Safer and Better?" In Febrile Neutropenia, 1–5. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Neutropeni"

1

Sara S, KILIC, Sukru Cekic, and Yasin Karali. "P370 Severe neutropenia in ADA2 deficiency." In Faculty of Paediatrics of the Royal College of Physicians of Ireland, 9th Europaediatrics Congress, 13–15 June, Dublin, Ireland 2019. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-epa.716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Price, D., C. Oromendia, E. Sanchez, K. C. Ma, E. Schenck, K. Nakahira, M. E. Choi, et al. "The Necroptosis Endotype in Neutropenic Critical Illness." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

García Basas, L., Á. Díaz Gago, J. Sáez De La Fuente, and AM Álvarez Díaz. "5PSQ-141 Analysis of ceftaroline associated neutropenia." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Grigoryan, T., G. Tamamyan, S. Danielyan, and P. Ghazaryan. "A Case Report of Neutropenic Enterocolitis in Armenia." In ISCAYAHL 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1701852.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lima, Eduarda Rabêlo, Pedro Erbet Belém Filho Morais, Luana Sales de Barros, and Erika Rolim Melo Gurgel. "TRATAMENTO DA NEUTROPENIA FEBRIL NOS PACIENTES EM USO DE QUIMIOTERAPIA: UMA REVISÃO DE LITERATURA." In I Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/642.

Full text
Abstract:
Introdução: A Neutropenia Febril (NF) pode ser definida através da temperatura oral ≥ 38,3ºC, no momento da aferição ou ≥ 38ºC durante 1 hora, além de uma contagem total de neutrófilos < 500/mm³ ou < 1000/mm³ com tendência de redução em 48 horas. Com o objetivo de estabelecer o tratamento adequado, deve-se realizar a estratificação de risco da NF, com o auxílio do índice de gravidade MASCC (Multinational Association for Supportive Care of Cancer), que pontua até 26 pontos. Objetivo: Revisar e descrever os principais aspectos da neutropenia febril nos pacientes em uso de quimioterapia, assim como as medidas mais eficazes para o seu tratamento. Material e métodos: Foi realizada uma pesquisa na literatura, utilizando as bases de dados PubMed e Scielo. Ao todo, foram revisados 7 artigos científicos, utilizando o descritor “Neutropenia febril em quimioterapia”, publicados entre os anos de 2016 a 2020. Resultados: O tratamento da NF envolve educação quanto a monitorização dos pŕoprios sintomas e tratamento medicamentoso. Em pacientes de baixo risco (MASCC ≥ 21 pontos), hemodinamicamente estáveis e na ausência de infecções de sítio, faz-se uso de antibioticoterapia oral com fluoroquinolona associada à amoxicilina-clavulanato. Em pacientes de alto risco (MASCC < 21 pontos) , faz-se beta-lactâmico antipseudomonas, carbapenêmicos ou piperacilina-tazobactam. Na presença de foco infeccioso, o tratamento deve seguir sua adequação para que haja a cobertura do real agente causador da infecção. Em idosos, é comprovada a relevância do uso de fator de crescimento como profilaxia e deve-se observar presença de uso crônico de glicocorticóides nesses grupos. Em crianças, recentemente tem-se optado pela antibioticoterapia oral nos pacientes de baixo risco, porém deve-se priorizar essa abordagem para pacientes cujas famílias possuam boa adesão medicamentosa. Conclusão: Em suma, a NF é uma emergência oncológica grave decorrente da quimioterapia, potencialmente fatal, desta forma deve ser diagnosticada e tratada o mais precocemente possível.
APA, Harvard, Vancouver, ISO, and other styles
6

Perez Contel, A., L. Soriano-Gutierrez, VJ de Pedro Ambrosio, P. Miralles-Albors, G. Puig Comas, S. Fernandez-Molina, and M. Gomez-Valent. "5PSQ-055 Does palbociclib mean neutropaenia?" In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.488.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ojaghi, Ashkan, and Francisco E. Robles. "Label-free identification of neutropenia using deep-ultraviolet microscopy." In Optical Diagnostics and Sensing XIX: Toward Point-of-Care Diagnostics, edited by Gerard L. Coté. SPIE, 2019. http://dx.doi.org/10.1117/12.2508899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Toepfner, N., M. Suttorp, J. Guck, and R. Berner. "Morphorheological changes of neutrophils in patients with neutropenic fever." In 31. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1645027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guisado Gil, AB, IM Carrión Madroñal, MT Garrido Martínez, and MD Santos Rubio. "5PSQ-037 Docetaxel induced neutropenic enterocolitis: a case report." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hijazi Vega, M., F. Fernández-Fraga, I. Gumiel-Baena, ME Martínez-Núñez, and T. Molina-García. "4CPS-035 Clinical pharmacokinetics of vancomycin in neutropenic patients." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.136.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Neutropeni"

1

Bovbjerg, Dana. Psychological Stress, Neutropenia and Infectious Disease in Patients Receiving Chemotherapy Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 1999. http://dx.doi.org/10.21236/ada383253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bovbjerg, Dana H. Psychological Stress, Neutropenia, and Infectious Disease in Patients Receiving Chemotherapy Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 1997. http://dx.doi.org/10.21236/ada344916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Neutropeni' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography